Tegaserod: A new 5-HT4 agonist

B. E. Lacy, S. Yu

Research output: Contribution to journalReview articlepeer-review


Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. Tegaserod is a selective serotonin receptor subtype 4 partial agonist designed to interact with the network of cells and nerves throughout the gastrointestinal tract that use serotonin. Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity. Specifically, it increases the peristaltic reflex and decreases visceral sensitivity. Clinical studies have shown that tegaserod improves symptoms of abdominal pain, bloating, and constipation in women with IBS. This article discusses the role of serotonin in gastrointestinal tract physiology, the structure and pharmacokinetic profile of tegaserod, and clinical applications of this new drug.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalJournal of clinical gastroenterology
Issue number1
StatePublished - 2002
Externally publishedYes


  • Constipation
  • Irritable bowel syndrome
  • Serotonin
  • Tegaserod
  • Zelnorm

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Tegaserod: A new 5-HT4 agonist'. Together they form a unique fingerprint.

Cite this